Vaginal, Urethral, Uterine Patents (Class 424/430)
  • Patent number: 10188629
    Abstract: Method of treating endometriosis and related indications, comprising the administration of Pro-EGCG, a synthetic and derivative product of epigallocatechin-3-gallate [(?)-EGCG]. Use of Pro-EGCG in the manufacture of a medicament for treating endometriosis and related indications. Pro-EGCG for use in the treatment of endometriosis and related indications.
    Type: Grant
    Filed: June 20, 2017
    Date of Patent: January 29, 2019
    Inventors: Tak-Hang Chan, Chi-Chiu Wang
  • Patent number: 10154856
    Abstract: A cervical transfer catheter (10) for transferring a therapeutic substance to an endocervix or other internal mucosal surfaces of a recipient, the catheter (10) comprising: a catheter body (12) having first and second lumens (14) and (16), the second lumen (16) being adapted, in use, to allow passage and retention of a structure containing the therapeutic substance that will be released slowly and continuously. The catheter (10) also comprises an inflatable balloon (20) provided at a distal end of the first lumen (14), the inflatable balloon (20) being designed to be as small as possible in its inflated condition while still being retained in the uterus by virtue of its shape.
    Type: Grant
    Filed: February 6, 2014
    Date of Patent: December 18, 2018
    Inventor: Mark Sillender
  • Patent number: 10137287
    Abstract: A drug delivery device is provided. In an embodiment, the device includes a device body having an elongated drug reservoir lumen, a drug positioned in the drug reservoir lumen, and at least one end plug positioned at an end of the device body, for example inserted in an end of the drug reservoir lumen. The end plug may include an aperture therethough, and the drug delivery device may be configured to release the drug from the drug reservoir lumen through the aperture.
    Type: Grant
    Filed: March 5, 2014
    Date of Patent: November 27, 2018
    Assignee: TARIS Biomedical LLC
    Inventors: Matthew Sansone, Karen Daniel, Grace Kim, Heejin Lee
  • Patent number: 10105445
    Abstract: This disclosure relates to a controlled-release composition containing a water-swellable linear polymer together with an active agent. The water-swellable linear polymer is obtained by reacting together: (a) a polyethylene oxide of number average molecular weight less than or equal to 4000 g/mol; (b) an aliphatic diol; and (c) a difunctional isocyanate. The ratio of components (a) to (b) to (c) is in the range of 0.01-0.1 to 1 to 1.01-1.1 in terms of equivalent weights. The amount of the polyethylene oxide is less than 50 wt % of the polymer. The polymer has a water swelling percentage of 20-100%.
    Type: Grant
    Filed: February 6, 2015
    Date of Patent: October 23, 2018
    Assignee: Ferring B.V.
    Inventors: Jukka Tuominen, Amaia Zurutuza, Mark Alexander Livingstone, Janet Anne Halliday
  • Patent number: 10064815
    Abstract: The subject matter of the present invention is pertinent to the field of vaginal delivery of pharmaceutically active agents. Embodiments of the instant invention disclose methods for treating a variety of progesterone related disorders by vaginal administration of a pullulan capsule and a fill formulation comprising one or more antiprogestins dispersed in a mixture of isopropyl palmitate or isopropyl myristate and a polyethylene glycol.
    Type: Grant
    Filed: April 22, 2015
    Date of Patent: September 4, 2018
    Inventors: Joseph S. Podolski, Kuang Hsu
  • Patent number: 9919018
    Abstract: The present disclosure provides compositions and methods for making and using topical compositions comprised of an isotonic, biome-friendly solution containing xylose and/or a Salvia extract. The compositions are useful for, for example, maintaining or enhancing female lower reproductive tract (LRT) homeostasis and physiological function. In particular, topical compositions of this disclosure can be formulated for use as a freshening, menopausal, fertility, and/or perineal composition.
    Type: Grant
    Filed: November 14, 2016
    Date of Patent: March 20, 2018
    Assignee: Fairhaven Health, LLC
    Inventors: Joanna E. Ellington, G. Dennis Clifton
  • Patent number: 9913871
    Abstract: The present disclosure provides compositions and methods for making and using topical compositions comprised of an isotonic, biome-friendly solution containing xylose and/or a Salvia extract. The compositions are useful for, for example, maintaining or enhancing female lower reproductive tract (LRT) homeostasis and physiological function. In particular, topical compositions of this disclosure can be formulated for use as a freshening, menopausal, fertility, and/or perineal composition.
    Type: Grant
    Filed: July 11, 2016
    Date of Patent: March 13, 2018
    Assignee: Fairhaven Health, LLC
    Inventors: Joanna E. Ellington, G. Dennis Clifton
  • Patent number: 9890106
    Abstract: Derivatives of plumbagin can be selectively cytotoxic to breast cancer cells. Derivative ‘A’ (Acetyl Plumbagin) has emerged as a lead molecule for testing against estrogen positive breast cancer and has shown low hepatotoxicity as well as overall lower toxicity in nude mice model. The toxicity of derivative ‘A’ was determined to be even lower than vehicle control (ALT and AST markers). The possible mechanism of action identified based on the microarray experiments and pathway mapping shows that derivative ‘A’ could be acting by altering the cholesterol-related mechanisms. The low toxicity profile of derivative ‘A’ highlights its possible role'as future anti-cancer drug and/or as an adjuvant drug to reduce the toxicity of highly toxic chemotherapeutic'drugs.
    Type: Grant
    Filed: March 13, 2013
    Date of Patent: February 13, 2018
    Assignee: KING ABDULLAH UNIVERSITY OF SCIENCE & TECHNOLOGY
    Inventors: Sunil Sagar, Mandeep Kaur, Luke E. Esau
  • Patent number: 9884049
    Abstract: The present invention provides microbicidal compositions comprising an octoxynol and a quinolizidine alkaloid compound or a source thereof, and methods of using the compositions. The quinolizidine alkaloid compound has a structure: or a pharmaceutically acceptable salt, solvate or stereoisomer thereof.
    Type: Grant
    Filed: July 10, 2015
    Date of Patent: February 6, 2018
    Assignee: ORION BIOTECHNOLOGY CANADA LTD.
    Inventors: Xuewu Zhang, Eric Leire
  • Patent number: 9877921
    Abstract: The invention provides compositions including epinephrine nanoparticles and methods for therapeutic use of the compositions in the treatment of conditions responsive to epinephrine such as a cardiac event or an allergic reaction, particularly anaphylaxis. The epinephrine nanoparticles can be incorporated into orally-disintegrating and fast-disintegrating tablet pharmaceutical formulations and can significantly increase the sublingual bioavailability of epinephrine, and thereby reduce the epinephrine dose required. Additionally, the invention provides methods for fabrication of stabilized epinephrine nanoparticles for use in the described compositions.
    Type: Grant
    Filed: September 15, 2016
    Date of Patent: January 30, 2018
    Assignee: NOVA SOUTHEASTERN UNIVERSITY
    Inventors: Mutasem Rawas-Qalaji, Ousama Rachid, Keith Simons, Estelle Simons
  • Patent number: 9827292
    Abstract: The present invention relates to the use of keratinocyte growth factor (KGF/FGF7) and pharmaceutical compositions thereof in the treatment of vaginal atrophy, dysuria, vaginal pain and/or vaginal dryness induced by a post-menopausal state, by surgical intervention, by illness and/or by chemotherapy or radiotherapy treatments.
    Type: Grant
    Filed: August 7, 2013
    Date of Patent: November 28, 2017
    Assignee: UNIVERSITA DEGLI STUDI DI ROMA “LA SAPIENZA”
    Inventors: Cinzia Marchese, Simona Ceccarelli, Antonio Angeloni
  • Patent number: 9801796
    Abstract: A cosmetic composition for reducing fair regrowth from four to seven terpene alcohols and including four sesquiterpene alcohols for reducing hair regrowth.
    Type: Grant
    Filed: February 6, 2015
    Date of Patent: October 31, 2017
    Assignee: ROBERTET S.A.
    Inventor: Anthony Pegard
  • Patent number: 9498434
    Abstract: A strip, which is both edible and dissolvable, is provided comprising a film and a dosage of at least 2% of the reference daily intake (RDI) of at least one dietary supplement for malnutrition or to prevent/treat alcohol induced hangovers. A method for treating malnutrition and/or preventing and treating alcohol-induced hangovers using a dissolvable orally administered strip.
    Type: Grant
    Filed: November 19, 2014
    Date of Patent: November 22, 2016
    Inventor: Alessandra Grassi
  • Patent number: 9457090
    Abstract: Bioactive hydroforming luminal liner compositions are formed of an absorbable crystalline amphiphilic polyether-ester-urethane dissolved in a liquid derivative of a polyether glycol that undergoes transformation into a tissue-adhering, resilient interior cover or liner for the controlled release of its bioactive payload at clinically compromised conduits in humans as in the case of bacteria- and yeast-infected vaginal canals, esophagi, and arteries following angioplasty.
    Type: Grant
    Filed: April 7, 2014
    Date of Patent: October 4, 2016
    Assignee: Poly-Med, Inc.
    Inventors: Shalaby W. Shalaby, David Ingram, Georgios Hilas, Sheila Nagatomi
  • Patent number: 9348972
    Abstract: Provided is a multiple birth prognostic tool that is used to analyze data in order to predict a multiple birth event in a female human patient undergoing an infertility treatment. The MBP prognostic tool may also be used to enhance the accuracy of diagnostic or prognostic tests that predict embryo viability. The MBP prognostic tool of the present invention may be clinic specific or it may be modified to be used in a multi-clinic approach.
    Type: Grant
    Filed: July 13, 2011
    Date of Patent: May 24, 2016
    Assignee: UNIVFY Inc.
    Inventor: Mylene Yao
  • Patent number: 9283182
    Abstract: The present invention relates to formulations of nucleotide reverse transcriptase inhibitors (NRTIs), preferably [2-(6-Amino-purin-9-yl)-1-methyl-ethoxymethyl]-phosphonic acid (tenofovir, PMPA), or a physiologically functional derivative thereof, suitable for topical application and their use in the prevention of HIV infections.
    Type: Grant
    Filed: September 24, 2010
    Date of Patent: March 15, 2016
    Assignees: The CONRAD Program of the Eastern Virginia Medical School (“CONRAD”), International Partnership for Microbicides, Inc.
    Inventor: Terrence C. Dahl
  • Patent number: 9168303
    Abstract: The present invention in general relates to an intravaginal delivery system as well as uses thereof and methods for manufacturing and use of the same. In particular the present invention relates to an intravaginal delivery system for the controlled release of one or more organic acids, such as lactic acid; said intravaginal delivery system being characterized in that it comprises a combination of ethylene vinyl acetate (EVA) copolymers and carboxylic polymers, such as for example methacrylic acid-methacrylic ester copolymers.
    Type: Grant
    Filed: July 12, 2012
    Date of Patent: October 27, 2015
    Assignee: Universiteit Gent
    Inventors: Jean Paul Remon, Chris Vervaet, Hans Verstraelen, Marleen Temmerman
  • Patent number: 9034377
    Abstract: The present invention relates to a plurality of dosage forms comprising a first dosage form and second dosage form each comprising a therapeutic agent, such as an opioid; wherein the dosage strength of the second dosage form is greater than that of the first dosage form; and wherein the steady state Cave and the steady state AUC of the first and second dosage forms are dose proportional and the single dose Cmax of the second dosage form is less than the minimum level for dose proportionality with respect to the first dosage form. The present invention also relates to methods of administering such dosage forms to a patient, as well as to kits comprising such dosage forms and instructions for administration of the dosage forms to a patient. The inventors believe that the dosage forms and methods of the present invention will lead to improved safety and patient acceptance.
    Type: Grant
    Filed: March 7, 2014
    Date of Patent: May 19, 2015
    Assignee: Purdue Pharma, L.P.
    Inventors: Curtis Wright, Robert Colucci, Ahmed El-Tahtawy
  • Patent number: 8992968
    Abstract: A fiber-reinforced composite ring for the controlled release of at least one bioactive agent includes a biocompatible matrix reinforced with absorbable/biodegradable fibers capable of providing the mechanical properties needed for inserting and maintaining the ring in a body cavity for a desired period of time. Such ring system as can be used for the intravaginal, intraperitoneal, and subcutaneous delivery of at least one bioactive agent, including those used as contraceptives, antimicrobial agents, and/or antiviral agents, as well as those for the treatment of cancer.
    Type: Grant
    Filed: February 20, 2013
    Date of Patent: March 31, 2015
    Assignee: Poly-Med, Inc.
    Inventor: Shalaby W. Shalaby
  • Patent number: 8992993
    Abstract: Biodegradable cross-linked particles, as well as related compositions and methods, are disclosed.
    Type: Grant
    Filed: April 8, 2013
    Date of Patent: March 31, 2015
    Assignee: Boston Scientific Scimed, Inc.
    Inventor: Robert E. Richard
  • Patent number: 8980304
    Abstract: The present invention relates to annular intravaginal devices comprising an aperture, methods of making, and uses thereof. The annular devices comprise an aperture extending into the device, the aperture having: (a) an interior diameter, and (b) an exterior entry diameter, wherein the exterior entry diameter of the aperture is less than the interior diameter of the aperture.
    Type: Grant
    Filed: August 18, 2011
    Date of Patent: March 17, 2015
    Assignee: Teva Women's Health, Inc.
    Inventor: Jiaxiang Tsao
  • Patent number: 8980303
    Abstract: The invention relates to medicine and pharmacology, more particularly to a pharmaceutical composition in the form of vaginal suppositories for treating candidal vaginitis and vulvovaginitis, containing antimycotics and prebiotics. The contents of the composition for therapeutic use make it possible to achieve the synergistic effect of stimulating the growth of the normal vaginal microflora through the presence of prebiotics and inhibiting the growth and eliminating pathogenic Candida fungi through the presence of modern antimycotics. Furthermore, the composition substantially contains such antimycotics to which representatives of the normal flora, i.e. lactobacilli and bifidobacteria, are insensitive. The method for treating mycetogenous or bacterial vaginosis, vaginitis and vulvovaginitis is carried out with the aid of the antimycotic and prebiotic pharmaceutical composition in a medicinal form for local application.
    Type: Grant
    Filed: September 30, 2008
    Date of Patent: March 17, 2015
    Assignee: Lugs International Ltd.
    Inventors: Aleksander Vladimirovich Dikovskiy, Oleg Valentinovich Dorozhko, Anatolievich Bor Rudoi
  • Publication number: 20150057746
    Abstract: A coating composition for drug eluting medical devices, which is capable of forming a drug coating layer that is not susceptible to peeling during delivery to a target tissue is provided. This coating composition contains: a water-insoluble drug; at least one selected from the group consisting of hyaluronic acid, alkanoyl hyaluronic acids obtained by substituting at least part of hydrogen atoms in the hydroxyl groups of hyaluronic acid with an alkanoyl group, and salts of hyaluronic acid and the alkanoyl hyaluronic acids; and at least one selected from the group consisting of amino-acid esters and salts thereof. A drug coating layer, a medical device and a method of treatment are also provided.
    Type: Application
    Filed: September 25, 2014
    Publication date: February 26, 2015
    Applicant: TERUMO KABUSHIKI KAISHA
    Inventors: Keiko YAMASHITA, Shigenori NOZAWA, Masashi ISOZAKI
  • Publication number: 20150056265
    Abstract: A coating composition for drug-eluting medical devices, which enables a medical device to be delivered to a target tissue for the purpose of treating an affected blood vessel part such as restenosis, without easy separation of a drug from the medical device during the delivery process is provided. The coating composition for drug-eluting medical devices contains a water-insoluble drug and at least one selected from the group consisting of ester compounds of amino acids, which have a hydropathy index of the amino acid of zero or less than zero, and salts thereof. A drug coating layer, a drug-eluting medical device and a method of treatment are also provided.
    Type: Application
    Filed: September 25, 2014
    Publication date: February 26, 2015
    Applicant: TERUMO KABUSHIKI KAISHA
    Inventors: Keiko YAMASHITA, Shigenori NOZAWA
  • Patent number: 8962010
    Abstract: An intravaginal drug delivery device comprises a device body comprising a hydrophobic carrier material having at least one channel defining at least one opening to the exterior of said device body, said at least one channel being adapted to receive at least one drug-containing insert; at least one drug-containing insert positioned in said at least one channel, said drug-containing insert capable of releasing a pharmaceutically effective amount of at least one drug suitable for intravaginal administration and containing about 1% to about 70% of at least one water-soluble release enhancer, both the drug and the water-soluble release enhancer dispersed in an insert carrier material; wherein said hydrophobic carrier material and said insert carrier material may be the same or different; and wherein said at least one drug-containing insert is exposed on said exterior of said device body when said intravaginal drug delivery device is in use.
    Type: Grant
    Filed: June 26, 2008
    Date of Patent: February 24, 2015
    Assignee: Warner Chilcott Company, LLC
    Inventors: David Aaron Woolfson, Karl Malcolm
  • Patent number: 8962011
    Abstract: An intrauterine device and more specifically an intracervical device (ICD) for the local release of drugs in the loco-regional treatment of tumours of the uterine cervix comprises an elongated stem (2) to be positioned in the cervical canal (15), this stem consisting of an inner hollow core (3) and a coating (4) containing a gradual-release drug, the stem being attached to: a first element (5) for blocking the stem (2) inside the uterine cavity (12), and located at the cranial or upper end; a second blocking element (7, 71) positioned inside the vagina (11), against the ectocervix (16), located at the caudal or lower end of the stem (2).
    Type: Grant
    Filed: January 29, 2009
    Date of Patent: February 24, 2015
    Assignee: Fondazione IRCCS Istituto Nazionale Dei Tumori
    Inventor: Francesco Raspagliesi
  • Publication number: 20150045610
    Abstract: Methods and compositions for modifying fertility and/or spermatogenesis or spermiogenesis in a male mammalian subject involve administering to the subject or contacting the subject's testis cells, germ cells or sperm with a composition that modifies the activation, nucleic acid expression, protein expression, signaling or activity of one or more T1R3 receptors or an intermediate in the signaling pathways thereof in the subject's testis cells or germ cells. In another embodiment, the method further involves administering to the subject or contacting the subject's testis cells, germ cells or sperm with a composition that modifies the activation, nucleic acid expression, protein expression, signaling or activity of G-?-gustducin, or an intermediate in the signaling pathways thereof. Methods for screening a test molecule for its effect on spermatogenesis or spermiogenesis or fertility and compositions for modifying spermatogenesis or spermiogenesis or fertility in a mammalian subject, e.g.
    Type: Application
    Filed: April 10, 2013
    Publication date: February 12, 2015
    Inventor: Bedrich Mosinger
  • Publication number: 20150017221
    Abstract: Provided is a cell adhesion inhibitor which exhibits low cytotoxicity and an excellent cell adhesion prevention effect; a tool and an apparatus each having a surface modified through application of the cell adhesion inhibitor thereto; a method for producing each of the surface-modified tool and apparatus; a biomedical structure and a production method therefor; and a microchannel device and a production method therefor. The invention provides a cell adhesion inhibitor comprising, as an active ingredient, a polymer comprising a repeating unit having a sulfinyl group in a side chain thereof.
    Type: Application
    Filed: December 26, 2012
    Publication date: January 15, 2015
    Inventors: Naoki Hayashi, Satoshi Hyugaji, Toshihiro Ogawa, Hidetoshi Miyamoto, Shin-ichirou Iwanaga
  • Publication number: 20150004212
    Abstract: The present invention is directed to linear, biodegradable polyesteramide (PEA) polymers synthesized with repeating units derived from aminophenol esters and diacids. These PEAs have a monomer repeat represented by as well as a variety of uses to coat, form or comprise medical devices, combination medical devices and pharmaceutical compositions, including sustained release formulations.
    Type: Application
    Filed: September 19, 2014
    Publication date: January 1, 2015
    Inventors: Arthur Schwartz, Satish Pulapura, Sarita Nethula, Archana Rajaram, Arikha Moses
  • Publication number: 20150004213
    Abstract: Drug delivery devices (e.g., polymeric vaginal rings) and related methods of manufacture and treatment are disclosed herein. In some embodiments, a manufacturing process for drug delivery devices is disclosed that includes a compounding extrusion process and an injection molding process. The various manufacturing parameters associated with these processes can be optimized to produce a drug delivery device with a favorable release profile and other characteristics. In particular, reducing the energy introduced into the system during manufacture can unexpectedly result in drug delivery devices with improved release profiles, especially in the case of large molecule drugs or in devices with a relatively low drug loading or drug particle size.
    Type: Application
    Filed: December 16, 2012
    Publication date: January 1, 2015
    Inventor: Eyal S. Ron
  • Patent number: 8905032
    Abstract: According to one claim of the invention, a method for occluding a fallopian tube in a vertebrate subject is described, which comprises comprising transcervically delivering a solid blocking material into the fallopian tube. In various embodiments, a fluid sealing material is delivered along with the solid blocking material. Other claims of the invention pertain to articles of manufacture, delivery devices and kits for use in occluding the fallopian tubes of a vertebrate subject.
    Type: Grant
    Filed: January 9, 2013
    Date of Patent: December 9, 2014
    Assignee: Boston Scientific Scimed, Inc.
    Inventors: Michael S. H. Chu, Jianmin Li, Hamid Davoudi
  • Patent number: 8900615
    Abstract: The subject invention provides a drug delivery system comprising at least one compartment consisting of (i) a drug-loaded thermoplastic polymer core, (ii) a drug-loaded thermoplastic polymer intermediate layer and (iii) a non-medicated thermoplastic polymer skin covering the intermediate layer, wherein said intermediate layer is loaded with (a) crystals of a first pharmaceutically active compound and with (b) a second pharmaceutically active compound in dissolved form and wherein said core is loaded with said second compound in dissolved form.
    Type: Grant
    Filed: November 9, 2012
    Date of Patent: December 2, 2014
    Assignee: Merck Sharp & Dohme B.V.
    Inventors: Rudolf Johannes Joseph Groenewegen, Wouter de Graaff
  • Patent number: 8883190
    Abstract: Provided herein are implantable or insertable biomedical devices comprising a substrate and a collagen inhibitor on or in said substrate, and methods of treatment using the same. In some embodiments, the device is a urethral, ureteral, or nephroureteral catheter or stent. Kits comprising the same are also provided.
    Type: Grant
    Filed: November 30, 2007
    Date of Patent: November 11, 2014
    Assignee: Wake Forest University Health Sciences
    Inventors: Steve J. Hodges, Anthony Atala, James J. Yoo
  • Publication number: 20140328895
    Abstract: The present invention discloses a liquid precursor composition adapted for application on a on a desired surface, this composition comprising: a. at least one therapeutic agent suitable for the treatment or prevention of a disorder or pathological condition, wherein said disorder or pathological condition excludes oral disorders, b. at least one acidic-pH sensitive polymer, c. at least one hydrophobic polymer, and d. a pharmaceutically acceptable volatile solvent, wherein a weight ratio between the at least one hydrophobic polymer and the at least one acidic-pH sensitive polymer is larger than 1.
    Type: Application
    Filed: March 25, 2012
    Publication date: November 6, 2014
    Applicant: Yissum Research Development Company of the Hebrew University of Jerusalem, Ltd.
    Inventors: Michael Friedman, Doron Steinberg, Eran Lavy
  • Publication number: 20140328893
    Abstract: The present invention relates to uses, methods and compositions for the treatment of pulmonary hypertension.
    Type: Application
    Filed: October 11, 2011
    Publication date: November 6, 2014
    Applicant: Institut National de la Sante et de la Recherche Medicale (INSERM)
    Inventor: Serge Adnot
  • Publication number: 20140314826
    Abstract: The invention provides a method for inhibiting bacterial attachment to a surface, the method comprising forming the surface from a polymer, or applying a polymer to the surface, wherein the polymer is a homopolymer formed from a (meth) acrylate or (meth) acrylamide monomer or a copolymer formed from one or more (meth) acrylate or (meth) acrylamide monomers, wherein the (meth) acrylate or (meth) acrylamide monomers are of formula (I) or (II): [H2C?CR?—C(?O)—O—]nR??(I) [H2C?CR?—C(?O)—NH—]nR??(II) wherein n is 1, 2 or 3, R? is independently H or CH3, R is an organic group having a total of from 2 to 24 carbon atoms, wherein the organic group includes an aliphatic or aromatic hydrocarbon moiety and wherein the organic group does not include any hydroxyl groups.
    Type: Application
    Filed: May 4, 2012
    Publication date: October 23, 2014
    Applicants: MASSACHUSETTS INSTITUTE OF TECHNOLOGY, THE UNIVERSITY OF NOTTINGHAM
    Inventors: Paul Williams, Morgan Russell Alexander, Martyn Christopher Davies, Robert Langer, Daniel Griffith Anderson
  • Patent number: 8865201
    Abstract: A hydrophilic matrix is disclosed which comprises: a) at least one polyacrylic acid derivative in preferred amounts of 0.5-40%, b) at least one cellulose ether in preferred amounts of 30-90% and c) at least one disintegrant in preferred amounts of 2-50%, with respect to the weight of the matrix. This matrix is used in combination with at least one pharmaceutically acceptable active principle for manufacturing solid bioadhesive controlled release formulations for the treatment of vaginal disorders, such as vulvovaginal candidiasis, bacterial vaginosis or trichomoniasis. According to a preferred embodiment, the matrix is used in amounts of about 5-60% and the active principle in amounts of about 2-70%, with respect to the weight of the formulation.
    Type: Grant
    Filed: June 21, 2007
    Date of Patent: October 21, 2014
    Assignee: Polichem SA
    Inventors: Stefano De Luigi Bruschi, Federico Mailland
  • Patent number: 8865200
    Abstract: Disclosed are sustained release compositions for vaginal or transdermal administration that contain a progesterone receptor modulator such as CDB-2914 (also referred to as VA-2914), and methods of using them for long term contraception or therapeutic purposes. Also disclosed are methods for making the compositions.
    Type: Grant
    Filed: July 8, 2005
    Date of Patent: October 21, 2014
    Assignee: Laboratoire HRA Pharma
    Inventors: Regine Sitruk-Ware, Yun-Yen Tsong
  • Patent number: 8858977
    Abstract: The subject invention provides a drug delivery system comprising at least one compartment consisting of (i) a drug-loaded thermoplastic polymer core, (ii) a drug-loaded thermoplastic polymer intermediate layer and (iii) a non-medicated thermoplastic polymer skin covering the intermediate layer, wherein said intermediate layer is loaded with (a) crystals of a first pharmaceutically active compound and with (b) a second pharmaceutically active compound in dissolved form and wherein said core is loaded with said second compound in dissolved form.
    Type: Grant
    Filed: November 9, 2012
    Date of Patent: October 14, 2014
    Assignee: Merck Sharp & Dohme B.V.
    Inventors: Rudolf Johannes Joseph Groenewegen, Wouter de Graaff, Henk Jan Out
  • Publication number: 20140242142
    Abstract: The present invention relates to the use of secreted proteins from mesenchymal stem cells and other cells for the treatment of myocardial infarction. In particular, the invention provides compositions and methods based on secreted proteins from mesenchymal stem cells and the genes encoding them.
    Type: Application
    Filed: June 25, 2012
    Publication date: August 28, 2014
    Applicant: National University of Ireland, Galway
    Inventors: Timothy O'Brien, Frank Barry, Claire Kavanagh
  • Publication number: 20140227192
    Abstract: The invention relates to a preparation for restenosis prevention. The preparations for restenosis prevention known as yet do not reach sufficient active agent concentrations in the affected sections of the vascular walls as higher doses cause undesirable side effects. The present invention is a preparation to which at least one antihyperplastic agent is added that has a distribution ratio between butanol and water .gtoreq.0.5. The lipophilic active agent is absorbed by the vascular wall fast and in sufficient quantity. The preparation may be a liquid that can pass through capillaries and may contain a contrast agent so that the active agent is transferred into the vascular wall without any additional effort while the usually required contrast radiograms are taken. The preparation may also be applied to a catheter.
    Type: Application
    Filed: April 17, 2014
    Publication date: August 14, 2014
    Applicant: Bayer Intellectual Property Gmbh
    Inventors: Ulrich SPECK, Bruno SCHELLER
  • Publication number: 20140227194
    Abstract: The invention relates to a preparation for restenosis prevention. The preparations for restenosis prevention known as yet do not reach sufficient active agent concentrations in the affected sections of the vascular walls as higher doses cause undesirable side effects. The present invention is a preparation to which at least one antihyperplastic agent is added that has a distribution ratio between butanol and water .gtoreq.0.5. The lipophilic active agent is absorbed by the vascular wall fast and in sufficient quantity. The preparation may be a liquid that can pass through capillaries and may contain a contrast agent so that the active agent is transferred into the vascular wall without any additional effort while the usually required contrast radiograms are taken. The preparation may also be applied to a catheter.
    Type: Application
    Filed: April 17, 2014
    Publication date: August 14, 2014
    Applicant: Bayer Intellectual Property Gmbh
    Inventors: Ulrich SPECK, Bruno SCHELLER
  • Publication number: 20140227193
    Abstract: The invention relates to a preparation for restenosis prevention. The preparations for restenosis prevention known as yet do not reach sufficient active agent concentrations in the affected sections of the vascular walls as higher doses cause undesirable side effects. The present invention is a preparation to which at least one antihyperplastic agent is added that has a distribution ratio between butanol and water .gtoreq.0.5. The lipophilic active agent is absorbed by the vascular wall fast and in sufficient quantity. The preparation may be a liquid that can pass through capillaries and may contain a contrast agent so that the active agent is transferred into the vascular wall without any additional effort while the usually required contrast radiograms are taken. The preparation may also be applied to a catheter.
    Type: Application
    Filed: April 17, 2014
    Publication date: August 14, 2014
    Applicant: Bayer Intellectual Property Gmbh
    Inventors: Ulrich SPECK, Bruno SCHELLER
  • Patent number: 8784868
    Abstract: A biodegradable biodelivery device is disclosed. The biodelivery device is formed from a polymer comprising the reaction product of a polyol and a polyacid. When exposed to water, the polymer degrades through hydrolysis. Of particular advantage, the polymer can be formed so as to be elastic and flexible. In one embodiment, the polymer is formed into a vaginal insert. As the polymer degrades, the polymer releases acid to a vaginal environment for decreasing the pH of the environment.
    Type: Grant
    Filed: March 5, 2013
    Date of Patent: July 22, 2014
    Assignee: Kimberly-Clark Worldwide, Inc.
    Inventors: Molly K. Smith, Kelly D. Arehart, Lei Huang, Shu-Ping Yang, Yanbin Huang
  • Patent number: 8770201
    Abstract: Condoms having an elastomeric layer and coating containing an anhydrous warming lubricant and at least one or more ingredients dispersed therein, the coating being disposed on one or both surfaces are provided. The ingredients disposed on the elastomeric layer can be solid particles or encapsulated ingredients that are insoluble in the anhydrous warming lubricant and soluble in water. Methods of producing and using these condoms are also provided.
    Type: Grant
    Filed: October 23, 2008
    Date of Patent: July 8, 2014
    Assignee: GlycoBioSciences Inc.
    Inventors: Michael S. Zedalis, Beng Sim Chuah, David M. Lucas, Angela M. Shiokawa, Jose R. Siqueira, Dave Narasimhan
  • Patent number: 8764715
    Abstract: Test methods for assessing irritation of portions of skin are provided. The method may include irritating a portion of skin by contacting the portion of skin with a chemical irritant; irritating the portion of skin by physical irritation; and assessing erythema or dryness of the portion of skin after irritating the steps. Alternatively, the method may include irritating a portion of skin with a chemical irritant; irritating the portion of skin by physical irritation; treating the irritated portion of skin by wiping the irritated portion of skin with a test sample; and assessing erythema or dryness of the portion of skin after the wiping step. A method of irritating a portion of skin to assess one of erythema and dryness may include irritating a portion of skin with a chemical irritant and irritating the portion of skin by physical irritation.
    Type: Grant
    Filed: July 28, 2011
    Date of Patent: July 1, 2014
    Assignee: The Procter & Gamble Comapny
    Inventor: Miranda Aref Farage
  • Patent number: 8753667
    Abstract: Multi-layered vaginal rings 2 comprising silicone elastomers and pharmaceutically active ingredients are disclosed. The rings comprise a number of layers, at least one of which contains a pharmaceutically active ingredient, and each of which is a silicone elastomer. The multiple layers preferably are produced from these layers of different compositions, including an inner layer 4, a middle layer 5, and an outer layer 6. After extrusion and simultaneous curing, however, the ring 2 includes a contiguous body which comprises a continuous silicone body providing unimpeded diffusion of the pharmaceutically active ingredient from the inner layer (s) 4 to the outer layer (s) 6. Methods of producing these vaginal rings and of using them are also disclosed.
    Type: Grant
    Filed: April 7, 2010
    Date of Patent: June 17, 2014
    Assignee: The Population Council, Inc.
    Inventors: Bruce Variano, Jeffrey Speck, Maria Teresa Sallent, Simone Evans
  • Patent number: 8741329
    Abstract: The subject invention provides a drug delivery system comprising at least one compartment comprising (i) a drug-loaded thermoplastic polymer core layer, (ii) a drug-loaded thermoplastic polymer intermediate layer and (iii) a non-medicated thermoplastic polymer skin covering the intermediate layer, wherein said core layer is loaded with crystals of a first (pharmaceutically) active compound and said intermediate layer is loaded with, crystals of the second (pharmaceutically) active compound.
    Type: Grant
    Filed: September 19, 2008
    Date of Patent: June 3, 2014
    Assignee: Merck Sharp & Dohme B.V.
    Inventors: Wouter de Graaff, Raymond Zeeman
  • Patent number: 8741330
    Abstract: Transluminal drug delivery method and device embodiments can include a urethral suppository formulated to prevent or treat diseases of the urethra and surrounding organs, such as interstitial cystitis or urethritis, by enhancing the absorption of a therapeutic agent of the suppository into body tissues without adversely affecting the natural defense mechanisms of these tissues. Adverse effects on the glycosaminoglycan (GAG) barrier can be mitigated or eliminated by the presence of a suitable polysaccharide in the suppository.
    Type: Grant
    Filed: September 14, 2012
    Date of Patent: June 3, 2014
    Inventors: Paul Zupkas, C. Lowell Parsons
  • Patent number: RE46912
    Abstract: The present invention relates to a lactic acid bacterium isolated from human mother's milk, more precisely a Lactobacillus gasseri BNR17 strain that is isolated from Korean mother's milk and has excellent probiotic activity including acid resistance, bile acid resistance and antimicrobial activity and weight gaining inhibitory effect as well. Again, the Lactobacillus gasseri BNR17 of the present invention has excellent acid resistance, bile acid resistance, enteric absorption activity and antimicrobial activity against pathogenic microorganisms, in addition to the weight gaining inhibitory effect by synthesizing indigestible polysaccharides from monosaccharides included in food taken and releasing the synthesized polysaccharides out of the body.
    Type: Grant
    Filed: November 10, 2014
    Date of Patent: June 26, 2018
    Assignee: BIONEER CORPORATION
    Inventors: Ji Hee Kang, Byeung I. You, Sung I. Yun, Han O. Park